Enrico Mini, M.D., Ph.D., is Professor of Medical Oncology at the University of Florence (UniFI), School of Human Health Sciences. He is Head of the Laboratory of Cancer Pharmacology and Chemotherapy at UniFI, and Director of the Unit of Translational Oncology at the Careggi University-Hospital of Florence. Dr. Mini received his M.D. in 1977 and his Ph.D. in 1988 from the University of Florence. He was Research Scientist from 1981 to 1985 at Yale University School of Medicine (Departments of Pharmacology and Internal Medicine) in the USA, were in 2010 he spent an additional period as a Visiting Professor. He was later Lecturer in Cellular Pharmacology (1983-1987) and in Cancer Pharmacology (1988-1992) at the Universities of Siena and Ferrara, respectively. Dr. Mini was appointed Associate Professor of Pharmacology in 1992 at the School of Medicine, UniFI, and grew up through the ranks to become Professor of Pharmacology in 2001 and Professor of Medical Oncology in 2008. He was also the Director of the Specialty School of Medical Oncology from 2011 to 2020. He previously served as Medical Staff Member at the Careggi University-Hospital Clinical Pharmacology Service (1993-2004) and was then Programme Director at the Unit of Cancer Pharmacology, Integrated Care Department of Oncology (2004-2014). He is a recognized expert in cancer pharmacology and therapeutics, clinical oncology, and translational cancer research. Dr. Mini has a double competence in cancer pharmacology and oncology, allowing him to master the mechanistic aspects of drug action and resistance as well as the discovery and application of pharmacogenomic markers of drug response and toxicity and their translation into clinical trials and medical practice. Dr. Mini acted as the principal investigator and/or coordinator within the framework of several funded research projects. His main research interests comprise molecular mechanisms of tumor drug resistance (in particular to antimetabolites and metal-based drugs), pharmacogenomics and pharmacogenetics of anticancer drugs, and medical treatment of colorectal cancer. He has been participant or the principal investigator of several key clinical trials in gastrointestinal cancers. Author of about 190 peer reviewed original articles and more than 70 reviews, editorials, and book chapters, and letters. Dr. Mini’s cumulative Impact Factor is more than 1900 and his H index 51 (Scopus). His research has contributed to elucidate the mechanisms of methotrexate and fluorouracil action and resistance, the biochemical bases of their drug synergism in experimental models and in cancer patients and to shape optimal administration schedules of these drugs in the clinic. Dr. Mini has received awards and honors for his research accomplishments. Among them, the Leukemia Society of America Special Fellow Award (New York) in 1982, the Lady Tata Memorial Trust Award (London) and the Alberico Benedicenti Italian Society of Pharmacology Special Mention Award (Milan) in 1988, the International Society of Antimicrobial Chemotherapy Fellow Award in 2019. He served as the Chairman of the Cancer Section of the International Society of Chemotherapy from 2007 to 2013. Currently, he is a member of the Steering Committee of the European Organization for Research and Treatment of Cancer (EORTC), Pan-European Trials in Adjuvant Colon Cancer (PETACC) and Member of various Study Groups of EORTC (e.g., Gastrointestinal Cancer Group, Lung Cancer Group, Pharmacology and Molecular Mechanism Group). He is also Editor of the Journal of Chemotherapy, Co-Editor of Oncology Research for the European Continent, and Editor of Pharmacogenetic Section of the Journal of Personalized Medicine. From 2018 he is the Coordinator of the Cancer Pharmacology Working Group of the Italian Society of Pharmacology.